Whole-exome sequencing in the evaluation of fetal structural anomalies: a prospective cohort study. Read more about Whole-exome sequencing in the evaluation of fetal structural anomalies: a prospective cohort study.
Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trial. Read more about Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trial.
Reporting of immune checkpoint inhibitor-associated myocarditis - Authors' reply. Read more about Reporting of immune checkpoint inhibitor-associated myocarditis - Authors' reply.
Robot-assisted radical cystectomy versus open radical cystectomy in patients with bladder cancer (RAZOR): an open-label, randomised, phase 3, non-inferiority trial. Read more about Robot-assisted radical cystectomy versus open radical cystectomy in patients with bladder cancer (RAZOR): an open-label, randomised, phase 3, non-inferiority trial.
Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis. Read more about Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis.
Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006). Read more about Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006).
Prediction of complicated disease course for children newly diagnosed with Crohn's disease: a multicentre inception cohort study. Read more about Prediction of complicated disease course for children newly diagnosed with Crohn's disease: a multicentre inception cohort study.
Transparency and availability of data for cancer research. Read more about Transparency and availability of data for cancer research.
